Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — 9M 2022 Earnings Presentation
13 slides from Zealand Pharma A/s's earnings presentation, Nov 10, 2022
Slide 1: 9M 2022 Interim report
9M 2022 Interim report Zealand Pharma 10 November 2022
Slide 2: Agenda
Agenda ➢ Recent company highlights ➢ R&D pipeline ➢ Financials 2 9M 2022 presentation 10 November 2022
Slide 3: Forward Looking Statement
Forward Looking Statement This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharm
Slide 4: Highlights during the last 6 months
Highlights during the last 6 months 1 Executed two 2 Phase 3 readouts from key 3 Advanced a portfolio in commercial partnerships programs obesity V-Go® sale to MannKind Dasiglucagon Phase 3 results Dapiglutide (GLP-1/GLP-2) in congenital hyperinsulinism Phase 1 data (at ESPE in September) BI 456906
Slide 5: Glepaglutide significantly reduced weekly PS volume
Glepaglutide significantly reduced weekly PS volume at Week 24 versus placebo in the Phase 3 EASE-1 trial • Randomized, double-blind, placebo-controlled Phase 3 trial • To evaluate the safety and efficacy of once and twice weekly dosing of 10 mg glepaglutide over 24 weeks of treatment * • Approximat
Slide 6: Dasiglucagon significantly reduced IV glucose requirement
Dasiglucagon significantly reduced the requirement for IV glucose in children with CHI in Phase 3 17103 trial • 2-part, Phase 3 trial to evaluate the efficacy of dasiglucagon in reducing glucose requirements in 12 children (aged 7 days to 12 months) with persistent CHI requiring continuous IV glucos
Slide 7: Our R&D pipeline includes a portfolio of novel assets targeting obesity
Our R&D pipeline includes a portfolio of novel assets targeting obesity Product Candidate* Preclinical Phase 1 Phase 2 Phase 3 Registration , diseases Dasiglucagon (S.C. Continuous Infusion) Congenital hyperinsulinism Rare Glepaglutide (GLP-2 Analog) Short Bowel Syndrome BI 456906 (GCGR/GLP-1R Dual
Slide 8: BI 456906 dose-dependently reduced HbA1c
BI 456906* dose-dependently reduced HbA1c in patients with T2D over 16 weeks • Dose-ranging trial of the weekly dual GCGR/GLP-1R agonist (BI 456906) in T2D on metformin Baseline HbA1c 7.9–8.2% Mean Absolute HbA1c 0 Change at Week 16 Placebo –0.25% Mean ± SE absolute change from -0,5 baseline in HbA1
Slide 9: BI 456906 dose-dependently decreased bodyweight
BI 456906* dose-dependently decreased bodyweight in patients with T2D over 16 weeks • Dose-ranging trial of the weekly dual GCGR/GLP-1R agonist (BI 456906) in T2D on metformin Baseline body weight: 93.0–100.1 kg Mean Relative Change in Bodyweight 0 After 16 Weeks’ Treatment -1 −1.20% Placebo DG-1: 0
Slide 10: Q1-Q3 2022 income statement
Q1-Q3 2022 income statement DKK million Q1-Q3 2022 Q1-Q3 2021 Revenue 80.1 95.1 Gross margin 79.5 84.1 Research and Development expenses -452.0 -421.8 Sales and Marketing Expenses -28.6 -51.3 Administrative Expenses -177.1 -179.7 Net Operating Expenses -657.7 -652.8 Other Operating Items -18.0 0.0 T
Slide 11: Balance sheet allows for continued investments
Balance sheet allows for continued investments Total Operating expenses* as of September Cash position of 30, 2022 of DKK 676 million DKK 1,516 million including October 4, 2022 private placement DKK million DKK million 1.000 1.600 900 1.400 800 1.200 700 1.000 600 500 800 400 600 300 400 200 200 10
Slide 12: 2022 financial guidance unchanged
2022 financial guidance unchanged The company will no longer provide guidance on net product revenue, reflecting the completion of the asset purchase agreement for V-Go® with MannKind Corporation and the completion of global license and development agreement for Zegalogue® with Novo Nordisk. In 2022
Slide 13: Q&A session
Q&A session• 1H 2022 presentation 11 August 2022 13